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RESUMO 
 
 
 
 
Citral (3,7-dimethyl-2,6-octadienal), um monoterpeno de cadeia aberta e 
principal componente bioativo do capim limão, apresenta diferentes 
propriedades farmacológicas, tais como: i) inibidor da atividade oxidante de 
células apresentadoras de antígenos (APCs), tais como os macrófagos; ii) 
inibidor da ativação do fator de transcrição pró-inflamatório NF-κB; iii) inibidor 
da expressão da enzima ciclooxigenase do tipo 2 (COX-2); e iv) ativador do 
fator  de  transcrição  pró-resolução   receptor   proliferador  de  peroxissomo 
(PPAR)-α e γ. Além disso, o citral atua como agonista inverso dos canais 
iônicos e receptores de potencial transitório (TRPs) expressos em neurônios 
sensoriais (TRPV1, TRPV3, TRPM8 e TRPA1), produzindo uma inibição de 
longa duração de TRPV1–3 e TRPM8, demonstrando potencial analgésico em 
diferentes tipos de dor. No entanto, até o presente momento, não existem 
relatos dos efeitos antiinflamatórios e analgésicos de citral em modelos 
inflamação   aguda,   assim   como   a   sua   interação   com   a   produção   de 
eicosanóides e modulação dos receptores do tipo Toll-like (TLR). Neste 
trabalho demonstramos que o tratamento oral com citral (nas doses de 50 – 
300 mg/kg) significativamente inibiu o edema de pata e a alodinia térmica 
induzidos pela carragenina. Além disso, o pré- tratamento com o citral inibiu a 
resposta inflamatória induzida por LPS e zimosan, ligantes dos receptores 
TLR4- e TLR2/dectina-1, respectivamente. Por fim, nossos resultados 
demonstram os efeitos antiinflamatórios e analgésicos do citral, os quais 
parecem estar relacionados à modulação dos receptores da imunidade inata, 
tais como o TLR4 e o TLR2/dectina-1.
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Abstract 
 
Citral (3,7-dimethyl-2,6-octadienal), a bioactive component of lemongrass, 
can inhibit  macrophage oxidant activity, and NF-κB activation, as well as COX-
2 expression and activation peroxisome proliferator-activated receptor (PPAR)-α 
and γ. In addition, citral activates TRP channels in sensory neurons (TRPV1 
and TRPV3, TRPM8, and TRPA1), and produces long-lasting inhibition of 
TRPV1–3 and TRPM8, while transiently blocking TRPV4 and TRPA1, 
demonstrating  analgesic  potential  for  allodynia  and  other  types  of  pain. 
However, there are no reports about the anti-inflammatory and analgesic effects 
of citral in induced  inflammation by carrageenan- and TLR-depend pathways 
and algesic  response.  In  this  study,  we  investigated  the  effect  of  citral  in 
experimental models of acute inflammation and nociception in mice. Oral 
treatment with citral (50 – 300 mg/kg) significantly inhibited carrageenan- 
induced paw edema and thermal allodynia. Furthermore, citral also modulated 
the inflammation induced by LPS and zymosan, a TLR4- and TLR2/dectin-1 
ligand, respectively. Our results demonstrate that oral citral treatment displayed 
anti-inflammatory and analgesic effects, and these effects seem to be related to 
its TLR4 and TLR2/dectin-1 modulation. 
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1. Introduction 
 
Inflammation is a physiological phenomenon that operates during severe 
perturbations of homeostasis, such as infection and injury, triggered by innate 
immune receptors that recognize pathogens and damaged cells (Noah, 2012). 
Recognition of microbial pathogens is an essential element for the initiation of 
innate immune responses such as inflammation, which is mediated by germline- 
encoded pattern-recognition receptors (PRRs) that recognize molecular 
structures that are broadly shared by pathogens, known as pathogen- 
associated molecular patterns (PAMPs) (Janeway, 1989; Geremia et al., 2014). 
Upon PAMP recognition, PRRs initiate a serious of signaling programs that 
execute the first line of host defensive responses necessary for killing infectious 
microbes. Moreover, PRR signaling simultaneously induces maturation of 
dendritic cells (DCs) and, hence, activate adaptive immunity (Kawai and Akira, 
2011). Toll-like receptors (TLRs), the first PRRs to be identified, are type I 
transmembrane proteins and comprise an ectodomain - that mediate the 
recognition  of  PAMPs  -  a  transmembrane  region,  and  cytosolic  Toll-IL-1 
receptor (TIR) domains - that activate downstream signaling pathways. To date, 
10 and 12 functional TLRs have been identified in human and mouse, 
respectively (Akira et al., 2006; Park and Lee, 2013). TLR signaling pathways 
are finely regulated by TIR domain-containing adaptors, such as myeloid 
differentiation (MyD) marker MyD88, TIRAP/Mal, TRIF and TRAM whose 
activation initiates downstream signaling events that directs to the secretion of 
inflammatory mediators, such as type I IFN, chemokines, nitric oxide (NO), 
cyclooxygenase (COX) and antimicrobial peptides (Kawai and Akira, 2010).
  
2 
Carrageenan is a generic name for a family of gel-forming and viscosifying 
polysaccharides, which are obtained by extraction from edible red seaweeds – 
mainly Rhodophyceae – and is a widely used test to determine anti- 
inflammatory activity and constitutes a simple and routine animal model for 
evaluation of pain at the site of inflammation without any injury or damage to the 
inflamed tissue (Seibert et al., 1994; Portanova et al., 1996; Zacharopoulos and 
Phillips 1997; Morris, 2003). The injection of carrageenan causes edema, 
increase tissue volume, and exacerbated sensitivity to thermal and mechanical 
stimuli (Chan et al., 1995; Khanna et al., 1997; Riendeau et al., 1997; Zhang et 
al., 1997). There are several mediators involved in carrageenan-induced 
inflammation. Histamine, serotonine (5-HT) and bradykinin (BK) are the first 
detectable mediators in the early phase of carrageenan-induced inflammation; 
prostaglandins (PGs), produced by COX pathway, are involved in the increased 
vascular permeability and are detectable in the late phase of inflammation. 
Local and/or systemic inflammation is associated with enhanced levels of the 
pro-inflammatory cytokines, such as TNF-α, IL-1, and IL-6 (Cuzzocrea et al., 
1999; Morris, 2003). Local neutrophils infiltration and activation also contribute 
to this inflammatory response by producing, among other mediators, oxygen- 
derived free radicals such as superoxide anion (O –) and hydroxyl radicals 
(OH-) (Posadas et al., 2004). 
Lipopolysaccharide (LPS), a bacterial endotoxin and TLR4 agonist, induces 
upregulation of proinflammatory cytokines by immune cells, including 
macrophages  and  DCs,  thereby mimicking  the  innate  immune  response  to 
bacterial infection (Laugerette et al., 2011; Manco et al., 2010; Rietschel et al., 
1994), and can serve as a short-term model for investigating the actions of
  
different classes of anti-inflammatory and analgesic drugs (Kanaan et al., 1997; 
Mehta et al., 2010; Sun  et al., 2010). Currently,  TLR4  signaling has been 
divided into MyD88-dependent and MyD88-independent (TRIF-dependent) 
pathways. Based on studies using MyD88-deficient macrophages, the MyD88- 
dependent pathway was shown to be responsible for proinflammatory cytokine 
expression, while the MyD88-independent pathway mediates the induction of 
Type I interferons and interferon-inducible genes (Lu et al., 2008; Park and Lee, 
2013). 
 
Zymosan, a polysaccharide from the cell wall of Saccharomyces cerevisiae, 
is composed primarily of glucan and mannan residues (Brown et al., 2002; Di 
Carlo, 1958; Reid et al., 2004). The recent discovery of PRRs and their role in 
innate immunity has led to a re-evaluation of our concepts of zymosan-induced 
inflammation (Gantner et al., 2003; Medzhitov, 1997). TLR2 is a receptor for 
zymosan, acting in collaboration with CD14 and TLR6 (Gantner et al., 2003; 
Ozinsky, 2000; Underhill, 1999). Thus, ligand  binding to  TLR2  induces the 
activation of transcriptional factor NF-κB with consequent production of 
inflammatory mediators, for instance IL-1β, IL-6 and IL-8, as well as the 
expression of the co-stimulatory molecule, like B7.1 (Medzhitov, 1997; Reid et 
al., 2004). Additionally, zymosan is able to induce maturation of DCs and to 
stimulate their production of IL-2, providing evidence for an essential link 
between the innate and the adaptive immune responses (Granucci, 2003; Roitt, 
2001). 
 
Citral (3,7-dimethyl-2,6-octadienal) (Fig. 1A), a monoterpene compound, is a 
mixture of tautomers geranial (trans-citral) and neral (cis-citral) found in the 
essential oils of numerous medicinal plants, especially, Cymbopogon citrates -
  
known as „„lemongrass‟‟.  Lemongrass is a widely used  plant, particularly in 
Southeast Asia and Brazil, where it is used as a food flavoring, as a perfume, 
and for its medicinal properties. Tea or essential oil from lemongrass is used as 
analgesic, anti-inflammatory and diuretic (Ferreira, 1984; Nishijima et al., 2014). 
Several studies have reported the medicinal use of Cymbopogon citrates and 
Citral, although little is known about its effect on the immune system. 
A very recent study conducted by Katsukawa and colleagues showed that 
Citral suppressed COX-2 expression and activated peroxisome proliferator- 
activated receptor (PPAR)-α and γ. In addition, PPARγ-dependent suppression 
of COX-2 promoter activity was observed in response to citral treatment, and in 
human macrophage-like U937 cells, citral suppressed both LPS-induced COX-2 
mRNA  and  protein expression,  dose-dependently  (Katsukawa  et  al.,  2010). 
Earlier  studies  have  demonstrated  that  Citral  acts  as  a  partial  agonist  of 
transient receptor potential (TRP) channels; it is useful for allodynia and other 
types of pain (Stotz et al., 2008). Furthermore, Citral has been shown to inhibit 
oxidant activity (Cheel et al., 2005, Barroso et al., 2011) and n i t r i c  
o x i d e  ( NO) production (Lee et al., 2008), macrophage activation, NF-κB 
activation, and cytokine production (Bachiega et al., 2011). However, to our 
knowledge, there are no reports on the anti-inflammatory and analgesic effects 
of Citral in carrageenan- and  TLR-depend  pathways  induced   inflammation  
and  algesic  response. Keeping the above data in mind, the purpose of 
the present study was  to investigate the effect of citral in experimental models 
of acute inflammation and nociception in mice.
  
2. Methods 
 
2.1. Experimental animals 
 
Experiments were conducted using male Swiss mice (25 - 40 g) obtained 
from  the  Universidade  Federal  de  Santa  Catarina.  The  mice  were  kept  in 
groups of four to six animals per cage, maintained under controlled temperature 
(22 ± 2°C) with a 12 h light/dark cycle (lights on at 07:00 h) and were given free 
access to food and water. All the procedures used in the present study were 
approved by the Institutional Ethics Committee of the Universidade Federal de 
Santa Catarina (CEUA-UFSC, protocol number PP00956), and were carried out 
in accordance with the “Principles of Laboratory Animal Care” from NIH 
publication No. 85 - 23. Similarly, the experimental procedures were in 
agreement with current guidelines for the care of laboratory animals and the 
ethical guidelines for investigations of experimental pain in conscious animals, 
as previously specified (Zimmermann, 1983). The number of animals and the 
intensity of noxious stimuli used were the minimum necessary to demonstrate 
consistent effects. Behavioral experiments were performed between 7:00 a.m. 
and 7:00 p.m. 
 
 
 
2.2. Drug treatment protocol 
 
Citral was stocked in amber glass, maintained at 4 °C and diluted in 5% 
Tween 80 solution made in saline (0.9% NaCl solution) to the desired 
concentration (50, 100 and 300 mg/kg) just before use. Citral or vehicle were 
orally administered by gavage (p.o.), 1 h before inflammatory stimulus and 
behavioral tests. Dexamethasone (0.5 mg/kg) was used as anti-inflammatory 
control and injected intraperitoneally (i.p.) one hour before intraplantar (i.pl.)
  
injections. The choice of dose drug based on previous data described in the 
literature (de Vasconcelos, et al., 2011; Nishijima, et al., 2014; Ponce-Monter, et 
al., 2010). 
 
 
 
2.3. Anti-inflammatory activity 
 
2.3.1. Carrageenan-induced hind paw edema model 
 
To induce inflammation, mice received subcutaneous injections in the plantar 
surface of λ-carrageenan (2.5%) in 50 μl of saline (0.9% NaCl solution) in the 
left (ipsilateral) hind paw and 50 μL of saline in the right (contralateral) hind 
paw, as previously described (de Vasconcelos, et al., 2011). The paw edema 
was measured plethysmographically (model 7150, Ugo Basile, Varese, Italy) 
both before and at 1, 2, 3, 4, 6, 24 and 48 h after carrageenan injection. The 
data obtained were expressed in ml. The percentage inhibition was calculated 
based on the data of the area under the time – curves (AUC ∑ different time- 
points after i.pl injection) using the following formula Inhibition = (1–T/V) x 100, 
where T means test and V means vehicle. 
 
 
 
2.3.2. LPS-induced paw edema 
 
LPS, a TLR4 ligand, from Escherichia coli 026:B6 was dissolved in saline 
(0.9% NaCl solution). Acute inflammation of mouse hind paws was induced 
according to published methods (Kanaan, et al., 1996). For the edema studies, 
LPS (50 µg in 50 µl of saline – concentration of 1 µg/µl) was injected 
subcutaneously into the plantar region of the left hind paw, and saline (50 µl) 
was injected into the right hind paw. The edema of the LPS-treated and control
  
paws were measured both before and after LPS injection at the time points, as 
described above. 
 
 
 
2.3.3. Zymosan-induced hind paw inflammation 
 
To induce a stimulus for TLR2 and dectin-1, mice received i.pl. injections of 
zymosan A from Saccharomyces cerevisiae (1%) in 20 μl of saline (0.9% NaCl 
solution) in the left (ipsilateral) hind paw and 20 μl of saline in the right 
(contralateral) hind paw (de Vasconcelos, et al., 2011). The paw edema was 
measured both before and after zymosan injection at the time points, by means 
of plethysmometer, as described above. 
 
 
 
2.4. Thermal allodynia test 
 
Pain nociception was determined using the paw immersion test, as described 
previously (Silva, et al., 2013). Briefly, mice were gently handled and their right 
paw was dipped into a water bath at 38°C, which is considered a non-noxious 
heat stimulus. This low-intensity stimulus yields baseline latencies (15 s) that 
are long enough to observe hyperalgesia or analgesia. Thus, the latency paw 
withdrawal response within 15 s was considered to be nociceptive behavior. To 
determine the basal thermal allodynia thresholds, all the experimental groups 
were submitted to a pre-injection evaluation (basal assessment) and they were 
re-evaluated at several time-points. After 15 s, if the animals did not withdrawal 
their paw, the stimulus was suspended. The animals were acclimatized for 1 h 
before behavioural testing. All withdrawal latencies were measured manually, 
and the observer was fully blinded to the experimental protocol for all tests.
  
2.5. Drugs and reagents 
 
Citral (95%), λ carrageenan, LPS (Escherichia coli 026:B6), zymosan A (from 
Saccharomyces cerevisiae) and dexamethasone were purchased from Sigma 
Chemical Co. (St. Louis, MO, USA). Other reagents used were all of analytical 
grade and obtained from different commercial sources. 
 
 
 
2.6. Statistical analysis 
 
Results are presented as means +/- SEM of measurements made on 4 – 6 
mice/group/experiment.   The   results   are   representative   of   one   or   two 
independent experiments. A statistical comparison of the data was performed 
by one or two-way ANOVA followed by Bonferroni or Newman–Keuls testing, 
depending on the experimental protocol. P-values less than 0.05 were 
considered significant. The statistical analyses were performed using GraphPad 
Prism 4 software (GraphPad Software Inc., San Diego, CA, USA). 
 
 
 
3. Results 
 
3.1. Effect of citral on paw edema induced by carrageenan 
 
In order to determine the anti-inflammatory activity of citral in acute-phase 
inflammation in vivo, carrageenan-induced paw edema model was conducted 
by intraplantar (i.pl.) injection of solution 2.5%. As expected, swelling of paw 
occurred rapidly after carrageenan-injection, with increase in volume at 1 h, 
which reached a maximum at 24 h (Fig. 2B and C). The oral treatment with 
citral (50, 100 or 300 mg/kg), 1 h beforehand, significantly inhibited the paw 
edema by i.pl. carrageenan injections (2.5%, 50 µl/paw), an effect that lasted for 
up to 24 h (Fig. 2B, C), with a percentage of inhibition of 57 ± 2.0%, 70 ± 4.0%
  
and 66 ± 3.5%, respectively, when compared with the carrageenan group 
(calculated on the basis of the area under the curve) (Fig. 1D). It is noteworthy 
that this effect was quite similar to that caused by dexamethasone (0.5 mg/kg, 
s.c.) – inhibition of 82 ± 5.5% – the clinical anti-inflammatory reference drug 
(p<0.001) (Fig. 2B D). 
 
 
 
3.2. Citral inhibits thermal allodynia induced by carrageenan in mice 
 
In order to investigate the possible anti-hypersalgesic effect of  citral, we 
evaluated the thermal allodynia induced by paw injection of carrageenan model. 
The thermal allodynia produced following i.pl. carrageenan injections (2.5%, 50 
µl/paw) was characterized by pronounced and long-lasting reduction on 
withdrawal latency from 15 ± 0.3 s at baseline for the naïve group to 8.0 ± 0.2 s 
for the carrageenan-group, especially, 15 min after i.pl. injection. This 
hypersalgesic behaviour was observed starting 15 min, reaching a maximum on 
30 min after injection and remained elevated for up to 150 min after 
carrageenan-injection (Fig. 2A). Significantly, citral (50, 100 or 300 mg/kg, p.o.) 
was effective to reduce the thermal allodynia with an inhibition of 62 ± 8.0%, 80 
± 6.0% and 62 ± 3%, respectively, when compared with the carrageenan group, 
based on AUC graph (Fig. 2B). Similar to the results obtained with citral, the 
treatment with dexamethasone (0.5 mg/kg, s.c.) was able to reduce the thermal 
allodynia induced by carrageenan inhibitions of 72 ± 7% (p<0.001). Based on 
these results, a dose of 50 mg/kg of citral was used in subsequent experiments 
to investigate some of the mechanisms underlying its anti-inflammatory effect.
  
3.3. Citral exerts anti-inflammatory effects by modulating TLR4 
pathway 
 
LPS is a ubiquitous molecule found on the surface of Gram-negative bacteria 
and is recognized by innate immune cells in humans. Slightly elevated levels of 
LPS persist in humans with chronic diseases and lifestyles that involve chronic 
smoking and drinking (Manco et al., 2010; Mehta et al., 2010; Sun et al., 2010; 
Laugerette et al., 2011;). The first events in the immune response to LPS occur 
outside of  the cell. LPS must first come  into  contact with  the  LPS-binding 
protein (LBP). The LPS–LBP complex can then be recognized by TLR4, acting 
in conjunction with MD-2 and CD14 (Park and Lee, 2013). Once this recognition 
has occurred, the TLR4 signaling cascade can commence, and upon ligation of 
TLR4 by LPS, signaling can proceed through a MyD88-dependent or MyD88- 
independent pathway. Herein, we assessed whether the treatment with citral 
could prevent LPS-induced paw-edema formation. The results in Figure 3 
indicate that LPS (1 µg/µl, i.pl.) induced paw-edema, an effect that lasted for up 
3 h (Fig. 3A). Of note, the acute oral administration of citral (50 mg/kg, p.o.), 1 h 
before   inflammatory   stimuli,   consistently   reversed   paw-edema   formation 
induced by LPS-injection (Fig. 3A), with an inhibition of 70 ± 6.0% (p<0.001), 
when compared with the LPS untreated-group, based on AUC graph (Fig. 3B). 
These data clearly show that even in presence of acute or intense inflammatory 
response, the oral administration of citral produced marked anti-inflammatory 
and analgesic effects, without any observable evidence of side effects.
  
3.4.  Anti-inflammatory  effect  of  citral  is  dependent  on  
TLR2/dectin-1 signaling pathway 
 
Zymosan, a yeast cell wall derivative, is recognized by dectin-1, a C-type 
lectin receptor for β-glucans (Brown et al., 2002, Reid et al., 2004) expressed in 
murine (Reid et al., 2004) and human (Yokota et al., 2001) DCs in conjunction 
with TLR2 (Gantner et al., 2003). In this set of experiments, we investigated 
whether the treatment with citral could inhibit the persistent inflammatory edema 
via TLR2/dectin-1-dependent mechanisms in mice. In the control group, i.pl. 
injection of   zymosan (1%, 20 µl/paw) increased paw-edema formation, 
beginning 2 h after injection, reaching a maximum between 3-4 h, and remained 
elevated for up to 48 h after inflammatory stimulus (Fig. 4A). Notably, the oral 
pre-treatment of mice with citral (50 mg/kg), 1 h before, inhibited zymosan- 
induced paw edema (1%, 20 µl/paw), with inhibition of 45 ± 5.0% (p<0.001) 
(Fig. 4A and B). Dexamethasone (0.5 mg/kg, s.c.), the reference drug used in 
the clinics, exhibited essentially the same degree of anti-inflammatory action 
observed for citral (50 mg/kg, p.o.) (Fig. 4A and B). Taken together, these 
series of results suggest that anti-inflammatory and analgesic effect of citral is 
critically dependent on TLR4 and TLR2/dectin-1 modulation. 
 
 
 
4. Discussion 
 
Citral is well known as a major component (more than 70%) of lemongrass oil 
(Rabbani et al., 2006), and its anti-fungal, anti-bacterial, anti-oxidant and free 
radical  scavenging  activities  have  been  described  previously  (Cheel  et  al., 
2005;  Lertsatitthanakorn  et  al.,  2006).  Herein,  we  investigated  the  anti- 
inflammatory and analgesic effects of citral in experimental models of acute
  
inflammation and nociception in mice, through modulation of eicosanoid- and 
TLR-depend pathways. Our results demonstrate that oral citral treatment 
displayed anti-inflammatory and analgesic effects, and these effects seem to be 
related to its TLR4 and TLR2/dectin-1 modulation. 
It is now well established that i.pl. injection of carrageenan produces a long- 
lasting edema and hyperalgesic response through central sensitization in 
response to the release of several pro-inflammatory mediators, such as 
prostaglandins (PGs), cytokines/chemokines and reactive oxygen species 
(ROS), which in turn increase the sensitivity of peripheral and central sensory 
pathways (Basbaum and Woolf, 1999; Minami et al., 2006). The present study 
showed that preventive oral treatment with citral produced a prominent inhibition 
of the edema and thermal allodynia induced by carrageenan, an action that 
lasted for up to 6 h and 150 min, respectively. This result confirms and extends 
the study conducted by Francisco et al., in which inflammatory response was 
inhibited by Cymbopogon citrates (Francisco et al., 2011). In addition, Lin et al. 
showed that citral inhibited croton oil-induced mice ear edema, dosage of 0.1 
and 0.3 mg/ear, with inhibition of 22 and 83%, respectively (Lin et al., 2008). 
Lipopolysaccharide (LPS), a component of gram-negative bacteria walls, is a 
well-recognized TLR4 agonist used as inflammation-model (Cunha et al., 2008; 
Kawai and Akira, 2005; Sugama et al., 2009). Herein, our results showed that 
citral markedly inhibited LPS-induced paw edema, in accordance of Shen et al., 
which showed the protective effect of citral on LPS-induced acute lung injury 
(ALI) by activating PPAR-γ (Shen  et al., 2015). Interestingly, this model is 
characterized by pulmonary edema, infiltration of neutrophils in the lung, and 
disruption of epithelial integrity (Karmpaliotis et al., 2002; Lucas et al., 2009).
  
PPAR-γ agonists have been reported to inhibit LPS-induced NF-κB activation, 
by inhibiting the phosphorylation of Iκ-B, which in turn inhibited p65 and p50 
translocation to the nucleus – an initial process for gene expression of several 
cytokines, such as TNF-α, IL-1β and IL-6 involved in the process of acute lung 
injury (Blackwell, 1997; Chen et al., 2007; Larsson et al., 1999; Lee et al., 2007; 
Parsons et al., 2005). Taken together, we suggest that a protective effect of 
citral  on  inflammation  is  associated,  in  part,  with  TLR4-pathways  inhibition 
which possibly infer in the inhibition of proinflammatory mediators and activation 
of PPAR-γ pathway. However, future studies will need to clarify this hypothesis, 
as well as to investigate whether citral could inhibit TLR4 through a MyD88- 
dependent or MyD88-independent pathway. 
Zymosan stimulates phagocytosis, the release of inflammatory 
cytokines/chemokines, upregulation of reactive oxygen and nitrogen species, as 
well   as   stimulates  adaptive   immune   responses   through   TLRs   pathway 
(Underhill, 1999; Gold, 2000). Following macrophage or DCs recognition of 
zymosan, both i) dectin-1, a lectin family receptor for β-glucans, and ii) 
TLR2/CD14 are recruited to phagosomes, which binds distinct components of 
the yeast cell wall and induces immune response. Previously studies have 
demonstrated that TLR stimulation leads to activation of NF-κB and production 
of proinflammatory cytokines such as TNF-α and IL-12 (Medzhitov, 1997; Reid 
et al., 2004). However, there are no reports on the effect of citral on models of 
inflammation induced by zymosan. Here, our findings revealed that the 
inflammation caused by zymosan was also greatly inhibited following oral pre- 
treatment with citral. As published previously, citral inhibited expression of 
inducible nitric oxide synthase (iNOS) and NF-κB (Lin et al., 2008), as well as
  
release of IL-1β and IL-6, leukocytes migration (Bachiega et al., 2011). 
Alternatively, it is possible to suggest that citral inhibits inflammatory response 
through TLR2/dectin-1-pathways inhibition associated with its ability to interfere 
with the release and/or expression of various relevant inflammatory and pain 
mediators and neutrophils migration. Nonetheless additional studies are 
necessary to test this hypothesis. 
In addition, we demonstrate that citral was effective to reduce thermal 
allodynia. A previous study demonstrated that citral has an anti-nociceptive 
effect when administered via i.p. route (Quintans-Junior et al., 2011). Moreover, 
Caterine and colleagues provides, the first evidence, of the anti-nociceptive 
effect of citral administered by oral route in acute and chronic pain model. 
Glutamate is a major excitatory neurotransmitter that transmits nociceptive 
signals by promoting the direct activation of receptors in nociceptive fibres. 
Once activated, these neurons release  several  inflammatory mediators and 
neuropeptides, which are involved in nociceptive transmission in the central and 
peripheral nervous systems (Fundytus, 2001; Millan, 1999). Thus, citral 
administered orally evoked an anti-nociceptive effect against the nociception 
induced by peripheral injection of glutamate, suggesting that this effect could 
occur through a direct action of citral on glutamatergic neurons in the spinal 
cord, which possibly correlates with our findings that the citral has analgesic 
properties, reducing the thermal allodynia when compared with the carrageenan 
group. Additional experiments are necessary to confirm whether or not the citral 
can selectively inhibit glutamatergic primary neurons in the spinal cord and 
dorsal root ganglion.
  
In summary, data presented herein demonstrate that citral has anti- 
inflammatory and analgesic activity in the rodent paw edema model induced by 
carrageenan, zymosan and LPS, suggesting a possible interaction with 
eicosanoid, TLR4 and  TLR2/dectin-1  pathways, both  involved  in  the  innate 
immune response. 
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Figures 
 
 
 
Figure 1. Effect of citral on carrageenan-induced paw edema in mice. (A) Chemical 
structure  of  the  open-chain  monoterpenoid  citral  (which  is  a  mixture  of  2 
isomers  (cis-isomer  neral  and  trans-isomer  geranial).  Representative 
photograph (B), graphical representation of the paw edema (C) and area under 
curve   (D)   from   1,   vehicle-treated   control;   2,   carrageenan-untreated; 
carrageenan plus: 3, citral (50 mg/kg, p.o.); 4, citral (100 mg/kg, p.o.); 5, citral (300 
mg/kg, p.o.); 6, dexamethasone (0.5 mg/kg, s.c.). Citral and dexamethasone were 
administered 1 h prior to carrageenan (2.5%) injection, and the mice were 
evaluated for paw edema at 1, 2, 3, 4, 6, 24 and 48 h post- carrageenan injection. 
Data are presented as mean ± SEM of 4–6 mice/group. #p<0.05 and 
##
p<0.001 
versus vehicle control group, *p<0.05 and **p<0.001 versus carrageenan-
untreated group (two-way ANOVA followed by Bonferroni’s test to A, and one-way 
ANOVA followed by Newmann–Keuls test to D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 2. Effects of citral on thermal allodynia induced by carrageenan. Time- course for the effects of citral (50, 
100 or 300 mg/kg, p.o.) and dexamethasone (0.5 mg/kg, s.c.) on thermal allodynia (A) and area under curve 
induced by carrageenan (2.5%)  injection.  Data  are presented  as  mean  ± SEM  of  4–6 mice/group. #p<0.05 
and ##p<0.001 versus vehicle control group, *p<0.05 and **p<0.001 versus carrageenan-untreated group (two-
way ANOVA followed by Bonferroni‟s test to A, and one-way ANOVA followed by Newmann–Keuls test to B).
  
 
Figure 3. Effect of citral on LPS-induced paws edema in mice. Time-course for the effects of 
citral (50 mg/kg, p.o.) and dexamethasone (0.5 mg/kg, s.c.) on paw edema (A) and area under 
curve induced by LPS (50 µg in 50 µl of saline – concentration of 1 µg/µl) injection. Data are 
presented as mean ± SEM of 4–6 mice/group. ##p<0.001 versus  vehicle  control group, 
*p<0.05 and  **p<0.001 versus carrageenan-untreated group (two-way ANOVA followed by 
Bonferroni‟s test to A, and one-way ANOVA followed by Newmann–Keuls test to B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 4. Effect of citral on zymosan-induced paw edema in mice. Time-course for the effects of citral (50 mg/kg, 
p.o.) and dexamethasone (0.5 mg/kg, s.c.) on paw edema (A) and area under curve induced by zymosan (1%) 
injection. Data are presented as mean ± SEM of 4–6 mice/group. ##p<0.001 versus vehicle control  group,  
*p<0.05  and  **p<0.001  versus  carrageenan-untreated  group (two-way ANOVA followed  by Bonferroni‟s  test  
to  A, and  one-way ANOVA followed by Newmann–Keuls test to B). 
 
